Champions Oncology

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Champions Oncology reports Q4 rebound, eyes revenue growth in 2025

Champions Oncology navigated challenges to achieve improved financial performance in Q4. The company is well-positioned with no debt and a cash-neutral strategy for 2025. Management's confidence in long-term prospects signals growth potential.

Champions Oncology (CSBR) reports robust Q1 earnings and growth outlook

Champions Oncology (CSBR) delivered a strong performance in Q1 2025, with revenue surpassing $14 million and notable margin improvements. Despite challenges faced in the past, the company has demonstrated resilience and improvement, positioning itself for future growth. Optimism from management and strategic initiatives highlight a promising outlook for Champions Oncology.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Champions Oncology (NASDAQ:CSBR) rose 1.08% in after-market trading after the company reported Q4 results.

Recap: Champions Oncology Q4 Earnings

Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Q2 2020 Results - Earnings Call Transcript

Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Fiscal Q1 2020 Results - Earnings Call Transcript

Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Q1 2020 Results - Earnings Call Transcript

BioSpecifics Technologies

Cantel Medical

RadNet

TransEnterix

In the long-run, does consistent market timing really matter to be a successful investor?

Simple Market Timing Strategies That Work - August 05, 2019

Champions Oncology Inc (NASDAQ:CSBR) files its latest 10-K with SEC for the fiscal year ended on April 30, 2019.

Champions Oncology Inc (CSBR) Files 10-K for the Fiscal Year Ended on April 30, 2019

Champions Oncology, Inc. (CSBR) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: Champions Oncology

Champions Oncology is a profitable, free cash flow positive contract research organization serving the immune-oncology and oncology market.

Letter To Champions Oncology: Time For Open Market Buys

While the company reported a small (and unexpected) net loss in Q3 FY2019, it was a result of a one-time operational issue related to managing aggressive growth.

Champions Oncology: Emerging Pick And Shovel Play On Cancer Drug Development

Champions Oncology, Inc (CSBR) CEO Ronnie Morris on Q3 2019 Results - Earnings Call Transcript

News for Champions Oncology Stock (CSBR)